Japanese ovarian trials: focus on irinotecan.
Irinotecan (CPT-11, Camptosar) has achieved a response rate of 23.6% in recurrent ovarian cancer. Irinotecan/cisplatin combination chemotherapy has shown a response rate of 33% in platinum-resistant ovarian cancer, and 76% when used as the initial regimen for ovarian cancer. Regarding dose-limiting toxicity, although neutropenia and diarrhea were observed, diarrhea was thought to cause no remarkable problems in the combination regimen examined. Based on these results, irinotecan is considered to be a useful drug in chemotherapy for ovarian cancer.
Sugiyama
Toru
T
Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan. sugiyama@iwate-med.ac.jp
Yakushiji
Michiaki
M
Ochiai
Kazunori
K
Noda
Kiichiro
K
D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002945:Cisplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000077146:Irinotecan; D007564:Japan / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D014481:United States / Q000453:epidemiology; D016387:Women's Health
D000970:Antineoplastic Agents; D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin